


European
Heart
Journal

European Heart Journal

the journal of the European Society of Cardiology



Volume 12
Supplement D
Pages 1-205

<i>List of contributors</i>	ii
<i>Foreword</i>	
B. MAISCH and E. G. J. OLSEN	1
Pericardioscopy—a new diagnostic tool in inflammatory diseases of the pericardium	
B. MAISCH and L. DRUDE	2
The role of pericardiectomy in pericardial disorders	
F. W. HEHRLEIN, R. MOOSDORF, M. PITTON and F. DAPPER	7
The value of endomyocardial biopsies in myocarditis and dilated cardiomyopathy	
E. G. J. OLSEN	10
Endomyocardial biopsy findings in cases with pericarditis or perimyocarditis	
Z.-X. YU, M. SEKIGUCHI, S. NUNODA, M. HIROE and S. HOSODA	13
Progress and challenges in the pathological diagnosis of myocarditis	
B. M. MCMANUS, L. H. CHOW, S. J. RADIO, S. M. TRACY, M. A. BECK, N. M. CHAPMAN, K. KLINGEL and R. KANDOLF	18
Right ventricular cardiomyopathy: Is there evidence of an inflammatory aetiology?	
G. THIENE, D. CORRADO, A. NAVA, L. ROSSI, A. POLETTI, G. M. BOFFA, L. DALIENTO and N. PENNELLI	22
Sarcoid heart disease—results of follow-up investigations	
H. SCHAEDEL, D. KIRSTEN, A. SCHMIDT, H. SCHMIDT and H.-J. STRAUSS	26
Modulation of the inflammatory response in experimental myocardial infarction	
R. M. BOHLE, S. PICH and H. H. KLEIN	28
Diagnostic assessment of macrophage phenotypes in cardiac transplant biopsies	
B. MUES, B. BRISSE, G. STEINHOFF, T. LYNN, T. HEWETT, C. SORG, N. ZUHDI and G. ROBBINS	32
Impaired myocyte function in vitro incubated with sera from patients with myocarditis	
L. DRUDE, F. WIEMERS and B. MAISCH	36
Effect of dexamethasone on coxsackievirus B2-infected rat beating heart cells in culture	
Y. Z. YANG, W. L. YUAN, Q. GUO, Z. X. GONG, T. S. ZHOW, J. Y. SHEN and H. Z. CHEN	39
Contractile responses of myocytes isolated from patients with cardiomyopathy	
S. E. HARDING, K. T. MACLEOD, S. M. JONES, G. VESCOVO and P. A. POOLE-WILSON	44
Molecular studies on enteroviral heart disease: patterns of acute and persistent infections	
R. KANDOLF, K. KLINGEL, H. MERTSCHING, A. CANU, C. HOHENADL, R. ZELL, B. Y. REIMANN, A. HEIM, B. M. MCMANUS, A. K. FOULIS, H. P. SCHULTHEI, B. E. ERDMANN and G. RIECKER	49
Molecular probes for detection of persisting enterovirus infection of human heart and their prognostic value	
L. C. ARCHARD, N. E. BOWLES, L. CUNNINGHAM, C. A. FREEKE, E. G. J. OLSEN, M. L. ROSE, B. MEANY, H. J. F. WHY and P. J. RICHARDSON	56
Molecular cloning of a heart antigen that cross-reacts with a neutralizing antibody to coxsackievirus B ₄	
K. W. BEISEL, J. SRINIVASAPPA and B. S. PRABHAKAR	60
Does CMV infection play a role in myocarditis? New aspects from in-situ hybridization	
U. SCHÖNIAN, M. CROMBACH and B. MAISCH	65
Murine cytomegalovirus myocarditis	
J. E. CRAIGHEAD, S. A. HUBER and W. B. MARTIN	69

Lyme borreliosis as a cause of myocarditis and heart muscle disease J. KLEIN, G. STANEK, R. BITTNER, R. HORVAT, C. HOLZINGER and D. GLOGAR	73
The possible value of synthetic peptides in the diagnosis and therapy of myocarditis and dilated cardiomyopathy P. L. SCHWIMMBECK, N. K. BLAND, H.-P. SCHULTHEISS and B. E. STRAUER	76
Prognostic determinants in conventionally treated myocarditis and perimyocarditis—Focus on antimyolemmal antibodies B. MAISCH, H. OUTZEN, D. ROTH, A. HIBY, M. HERZUM, C. HENGSTENBERG, G. HUFNAGEL, U. SCHÖNIAN and K. KOCHSIEK	81
Humoral immune response against contractile proteins (actin and myosin) during cardiovascular disease I. K. DE SCHEERDER, M. DE BUYZERE, J. DELANGHE, A. MAAS, D. L. CLEMENT and R. WIEME	88
High voltage activated calcium channels: molecular composition and function V. FLOCKERZI, E. BOSSE, M. BIEL and F. HOFMANN	95
The Ca-channel as cardiac autoantigen U. KÜHL, B. MELZNER, B. SCHÄFER, H.-P. SCHULTHEISS and B. E. STRAUER	99
Nifedipine affects neutrophil functions by a non-calcium-mediated mechanism K. NALINI, K. ANDRABI, N. K. GANGULY and P. L. WAHI	105
Genetics of Coxsackie B3(CVB3)myocarditis N. VAN HOUTEN and S. A. HUBER	108
Elution of autoantibodies from the hearts of Coxsackievirus-infected mice D. A. NEUMANN, J. R. LANE, A. LAFOND-WALKER, G. S. ALLEN, C. FRONDOZA, A. HERSKOWITZ and N. R. ROSE	113
Cardiac myosin-induced myocarditis as a model of postinfectious autoimmunity N. NEU, R. KLIEBER, M. FRÜHWIRTH and P. BERGER	117
Natural history of coxsackievirus B3-induced myocarditis in ACA/Sn mice: viral persistence demonstrated by quantitative in situ hybridization histochemistry G. MALL, K. KLINGEL, M. ALBRECHT, M. SEEMANN, P. RIEGER and R. KANDOLF	121
Anti-coxsackievirus B3 neutralizing antibodies with pathological potential C. J. GAUNTT, H. M. ARIZPE, A. L. HIGDON, M. M. ROZEK, R. CRAWLEY and M. W. CUNNINGHAM	124
Dilated cardiomyopathy and myocarditis: monoclonal antibodies to diseased heart tissues C. J. F. SPRY and P.-C. TAI	130
Induction of cytokine release from human monocytes by coxsackievirus infection A. HENKE, M. NAIN, A. STELZNER and D. GEMSA	134
Expression of MHC class I and II antigens and the IL-2 receptor in rejection, myocarditis and dilated cardiomyopathy G. HUFNAGEL and B. MAISCH	137
Signs of endothelial inflammation in human heart allografts G. STEINHOFF, M. BEHREND and A. HAVERICH	141
Immune response to the endothelium in myocarditis, dilated cardiomyopathy and rejection after heart transplantation C. HENGSTENBERG, M. L. ROSE, E. G. J. OLSEN and B. MAISCH	144
Immunocytochemical markers of activation in cardiac transplant rejection M. ROSE, C. PAGE, C. HENGSTENBERG and M. YACOB	147
Serum neopterin—possible immunological marker of myocardial inflammation in patients with dilated heart muscle disease M. SAMSONOV, E. NASSONOV, S. KOSTIN, A. SAMKO, L. ALEXANDROVA, V. MASENKO, V. NAUMOV, V. MAREEV, S. SHEVLYAGIN and V. ZHDANOV	151
Naturally occurring anti-idiotypic antibodies—mechanisms for autoimmunity and immunoregulation? H. WEREMEICHIK, A. MORASKA, M. HERZUM, A. WELLER and S. A. HUBER	154
Autoimmune determinants of rheumatic carditis: localization of epitopes in human cardiac myosin A. DELL, S. M. ANTONE, C. J. GAUNTT, C. A. CROSSLEY, W. A. CLARK and N. W. CUNNINGHAM	158
Release of oxygen free radicals by macrophages and neutrophils in patients with rheumatic fever V. KUMAR, N. K. GANGULY, I. S. ANAND and P. L. WAHI	163
Experimental giant cell myocarditis induced by cardiac myosin immunization T. IZUMI, M. KODAMA and A. SHIBATA	166
Myopathies and cardiomyopathies: histochemical and biochemical analyses H. REICHMANN and R. GOLD	169
Myocardial catecholamine concentrations in dilated cardiomyopathy and heart failure of different origins V. REGITZ, B. LEUCHS, C. BOSSALLER, J. SEHESTED, M. RAPPOLDER and E. FLECK	171
Beta-adrenoceptor antibodies and genetics in dilated cardiomyopathy—An overview and review C. J. LIMAS and C. LIMAS	175

Autoantibodies against the β -adrenergic receptor in human myocarditis and dilated cardiomyopathy: β -adrenergic agonism without desensitization G. WALLUKAT, M. MORWINSKI, K. KOWAL, A. FÖRSTER, V. BOEWER and A. WOLLENBERGER	178
Diastolic dysfunction as a precursor of myocardial damage by reoxygenation K. H. KONZ, M. HAAP, R. A. WALSH, R. F. BURK and L. SEIPEL	182
Effect of mediators on coronary circulation G. ERTL, B. BAUER, S. NEUBAUER, W. SCHORB and K. KOCHSIEK	187
Hormones in heart failure—regulation and counterregulation A. J. G. RIEGGER	190
Clinical aspects and haemodynamics in the follow-up of dilated cardiomyopathy and myocarditis F. CAMERINI, R. BUSSANI, DI. LENARDA, G. LARDIERI, L. MESTRONI, D. MIANI, B. PINAMONTI, A. SALVI, F. SILVESTRI and G. SINAGRA	193
Therapeutic alternatives in dilated cardiomyopathy—A review of current options F. X. KLEBER	197
Treatment of experimental murine coxsackie B ₃ myocarditis M. HERZUM, S. A. HUBER, R. WELLER, R. GREBE and B. MAISCH	200
Immunomodulating therapy in viral myocarditis: Effects of tumour necrosis factor, interleukin 2 and anti-interleukin-2 receptor antibody in an animal model A. MATSUMORI, T. YAMADA and C. KAWAI	203

High voltage activated calcium channels: molecular composition and function

V. FLOCKERZI, E. BOSSE, M. BIEL*, R. HULLIN* AND F. HOFMANN*

Medizinische Biochemie, Universität des Saarlandes, 6650 Homburg, Germany, and * Institut für Pharmakologie und Toxikologie Technische Universität München 8000 München 40, Germany

KEY WORDS: Ca²⁺ channel, cDNA cloning, phosphorylation, expression.

Voltage-activated calcium channels comprise a group of similar yet distinct proteins or protein complexes that differ in electrophysiological properties, modulation by phosphorylation and GTP-binding proteins and in their relative sensitivity to organic calcium channel blockers. Cloning of the cDNA of L-type calcium channels from skeletal muscle, heart and smooth muscle opens the way to understanding the molecular basis of channel function and regulation and provides means of studying calcium channels in other tissues.

Introduction

Voltage activated calcium channels are membrane-spanning proteins that allow the controlled entry of calcium ions into the cytoplasm of cells and thereby contribute to the genesis of action potentials^[1-4]. By raising [Ca]_i, calcium channels transduce electrical signals to chemical signals that command changes in secretion, metabolism, contraction or excitability when decoded by appropriate calcium receptor proteins such as calmodulin, troponin, and calcium-activated potassium channels. Calcium channels are vital for several processes of the cardiovascular system. In the healthy heart, they are essential for generation of normal cardiac rhythm, to induce propagation through the atrioventricular node, and for contraction in atrial and ventricular muscle. In diseased myocardium, calcium channels can contribute to abnormal impulse generation and cardiac arrhythmias. In blood vessels they provide a direct supply of activating calcium, which controls smooth muscle contraction and vascular tone. At least three types of voltage-activated calcium channels have been distinguished on the basis of their voltage dependence, time dependence, conductance and pharmacology: namely, L-, T- and N-type channels (Table 1)^[1-3]. L-type channels are virtually ubiquitous and are the major pathway for voltage-gated calcium entry in heart and most kinds of smooth muscle. The L-type channel is high voltage activated, has a high Ca²⁺ conductance contributing to a long-lasting current and is readily blocked by calcium channel blockers such as nifedipine and verapamil. In cardiac muscle, β -adrenergic agonists increase the probability of this channel type being open,^[5] either by phosphorylation of the channel itself or by stabilizing the open state via the α subunit of the GTP-binding protein Gs^[3,6]. Although work on many cell systems has contributed to current understanding of calcium channel function the structural properties of the channel have been investigated most thoroughly in skeletal muscle which is particularly rich

in the specific high affinity receptor for calcium channel blockers (CaCB receptor)^[7].

Biochemistry of the skeletal muscle CaCB receptor/calcium channel

When purified from rabbit skeletal muscle, the calcium channel consists of three main subunits with molecular masses of 165 000 (CaCB receptor or α_1 subunit), 55 000 (β) and 32 000 Da (γ) (Table 2)^[8-12]. A further polypeptide consisting of a disulphide-linked dimer of a 130 000 (α_2) and a 28 000 (δ) protein is present in this preparation at a variable concentration^[12]. The subunits have been reconstituted to functional calcium channels which were modulated by phosphorylation^[13] and by monospecific antibodies for the α_1 , β and γ subunits^[14,15]. The CaCB receptor is the principal transmembrane unit, which forms the ion-conducting pore. This protein binds calcium channel blockers^[4,12,16,17] such as dihydropyridines and phenylalkylamines with 1:1 stoichiometry (for each compound one site per CaCB receptor) and is phosphorylated in vitro at Ser₆₈₇ by cAMP-dependent protein kinase^[18]. The β subunit, but not the γ subunit, contains multiple phosphorylation sites^[19]. Neither of the subunits binds calcium channel blockers. Attempts to isolate only the CaCB receptor under non-denaturing conditions have not been successful so far, suggesting that the β and γ subunit stabilize the channel in a high-affinity CaCB-binding conformation. At present, it is not known whether the 130/28 kDa protein belongs to this structure^[11] or is only a contaminant.

Molecular biology of the skeletal muscle calcium channel

Complementary DNAs for the skeletal muscle calcium channel were isolated on the basis of peptide sequences derived from the purified proteins^[17,20-22]. The cDNA of the CaCB receptor encodes a large polypeptide (212 kDa) which is structurally similar to voltage activated sodium channels. As with the sodium channel, the

Address for correspondence: Privatdozent Dr Veit Flockerzi, Medizinische Biochemie, Universität des Saarlandes D-6650 Homburg/Saar, Germany.

Table 1 Properties of the three types of mammalian voltage activated calcium channels

Channel type	T	N	L
<i>electrophysiology</i>			
threshold potential	low	high	high
inactivation	fast	intermediate	slow
<i>pharmacology</i>			
dihydropyridine-sensitive	—	—	+
phenylalkylamine block	(+)	—	+
* Ω -conotoxin block	(+)	+	+
inorganic ion block	Ni ²⁺	Cd ²⁺	Cd ²⁺
occurrence	ubiquitous	neurons	ubiquitous

* Omega-conotoxin appears to bind to N-type calcium channels in brain thereby blocking channel function (McCleskey, EW, Fox AP, Feldman DH *et al.* 1987; Proc Natl Acad Sci USA 84: 4327-31).

Table 2 Subunit structure of the skeletal muscle calcium channel

subunit	M _r (kDa)	CaCB	Phosphorylation	Glycosylation	Primary structure	Possible function
α_1 (CaCB-receptor)	165	dhp paa dil	Ser ₆₈₇	weak	1873 aa	ion-conducting voltage sensor unit
β	55	—	Ser ₁₈₂ Thr ₂₀₅	no	524 aa	regulatory
γ	32	—	—	strong	222 aa	regulatory
α_2	130	—	—	strong	1106 aa	?
δ	28	—	—	strong	n.d.	?

Abbreviations: CaCB, calcium channel blocker; dhp, dihydropyridine; paa, phenylalkylamine; dil, diltiazem; aa, amino-acid; n.d., not determined.

CaCB receptor possesses four internal repeats which are 48 to 55% homologous (Fig. 1). Each repeat is composed of five putative transmembrane α -helices and one amphiphilic segment, S4, which contains five or six positively charged amino-acids. Homologous S4 segments are present in the potassium and sodium channels from a variety of different species suggesting that this highly conserved segment is an essential part of a voltage activated cation channel. It is thought that S4 responds to a change in the membrane potential with a slight intramembrane shift of its positive charges, and thereby induces a conformational change in the protein which leads to channel opening or closing^[23]. The deduced amino-acid sequence of the skeletal muscle CaCB receptor contains seven potential phosphorylation sites for cAMP-dependent protein kinase^[17]. One of these sites, Ser₆₈₇, is readily phosphorylated by cAMP kinase *in vitro*^[18]. Microinjection of an expression plasmid carrying the CaCB receptor cDNA induces a high voltage activated calcium current in dysgenic muscle^[24] and in non-excitabile mouse L cells^[21,22]. In addition, it restores excitation contraction coupling in myocytes of dysgenic (mdg) mice^[24], suggesting that the skeletal muscle CaCB receptor functions both as a calcium channel and as a voltage sensor coupling extra-cellular excitation to the release of calcium from the sarcoplasmic reticulum. It is not known whether these two functions require the presence of the other subunits.




Figure 1 Transmembrane folding model of the CaCB subunit (upper part) and conservation of the amino-acids of the positively charged segment S4 among voltage activated cation channels (lower part). The internal repeats I, II, III and IV each composed of six transmembrane segments are shown. P indicates phosphorylation site which is phosphorylated *in vitro* in the skeletal muscle CaCB receptor (□) and which is conserved in the skeletal, cardiac and smooth muscle CaCB receptor (○). Alignment of S4 segments from voltage activated Na⁺, Ca²⁺ and K⁺ channels. The one letter code for amino-acids is used. R, Arg; K, Lys.

The β subunit consists of 524 amino-acids^[25]. It contains four homologous α helical segments. In contrast to the CaCB receptor, the β subunit is substantially hydrophilic suggesting that it is a peripheral membrane protein. Further analysis of its primary structure reveals multiple potential phosphorylation sites, two of which, Ser₁₈₂^[25] and Thr₂₀₅^[26], are readily phosphorylated by cAMP-dependent protein kinase *in vitro*.

The γ subunit consists of 222 amino-acids^[27,28]. It is very hydrophobic and contains four typical membrane spanning regions. Thus it is reasonable to assume that the amino and carboxy termini are localized intracellularly whereas the four hydrophobic segments cross the cell membrane^[27]. This model (Fig. 2) is consistent with the two potential N-glycosylation sites being located on the extracellular site. *In vivo* the γ subunit is highly glycosylated, and this accounts for the difference in molecular mass between the natural γ subunit (≈ 32 kDa) and the predicted mature unglycosylated polypeptide (≈ 25 kDa). The primary structure of the γ subunit shows no homology to other known protein sequences. However, 34.1% of a sequence of 44 amino-acids within the γ subunit are identical with a similar sequence of the multidrug resistance protein 2 (mdr2 or P-glycoprotein)^[29]. Interestingly, mdr2 binds calcium channel blockers^[30]. Although the γ subunit does not bind these compounds by itself, it cannot be excluded that the similar amino-acid sequences are indirectly involved in calcium channel blocker binding to the CaCB receptor and the mdr2 protein, respectively.

L-Type calcium channel proteins in smooth and cardiac muscle

Complementary DNAs for the CaCB receptor have been isolated from rabbit heart^[31] and rabbit smooth muscle^[32] on the basis of sequence homology with their skeletal muscle counterpart. Both the cardiac and smooth muscle cDNAs encode large polypeptides (2171 and 2166 amino-acids, respectively) showing an overall homology of 66% (cardiac) and 65% (smooth muscle) to the skeletal muscle CaCB receptor. The amino-acid sequence of the smooth muscle CaCB receptor differs from the rabbit heart receptor at four sites comprising the amino terminus, segments IS6 and IVS3 and an intervening sequence between repeats I and II^[32]. Both




Figure 2 Transmembrane folding model of the γ subunit of the skeletal muscle calcium channel. The four transmembrane segments are indicated. Amino and carboxy termini are localized intracellularly. Potential N-glycosylation sites (Asn 43 and Asn 79) are indicated in the first extracellular loop.

channel proteins are differentially expressed. The mRNA of the cardiac channel is exclusively expressed in heart whereas the mRNA of the smooth muscle channel is present in airway and vascular smooth muscle cells, which exist in lung, trachea, heart, aorta and brain (Table 3)^[32]. Cardiac ventricular and smooth muscle myocytes express mainly high voltage activated calcium channels, with the slow inactivating properties classified as L-type, which are sensitive to calcium channel blockers. In agreement with this, microinjected synthetic RNA derived from the cloned cardiac and smooth muscle CaCB receptor cDNA directs the synthesis of similar channels in *Xenopus* oocytes^[31,32]. These results indicate that the cardiac and smooth muscle CaCB receptors alone are sufficient to induce calcium channel activity.

Conclusion

In vivo, the skeletal muscle CaCB receptor functions both as voltage sensor, which directly controls release of calcium from the sarcoplasmic reticulum, and as calcium channel. The similar tissue specific expression of the mRNA encoding the skeletal muscle CaCB receptor (α_1), β and γ subunit (Table 3) suggests that the three proteins contribute to these functions. In contrast to the skeletal muscle CaCB receptor, the cardiac receptor functions only as calcium channel and, when injected into myotubes of dysgenic mice, it releases calcium by an indirect calcium-dependent mechanism^[33]. Hence, different CaCB receptor proteins and their association with other components, such as β and γ subunits, may

Table 3 Hybridization specificity of the calcium channel subunits

cDNA probe	smooth	cardiac	skeletal
CaCB receptor			
common	8.9/(15.5)	8.9/(15.5)	6.5/(8.9)
smooth	8.9/(15.5)	8.9/(15.5)	—
cardiac	—	8.9/(15.5)	—
skeletal	—	—	6.5
α_2 subunit	8.0	8.0	8.0
β subunit	—	—	1.9
γ subunit	(1.3)	—	1.3

Numbers indicate length of hybridizable mRNAs of rabbit smooth, cardiac, and skeletal muscle in kilobases using the respective cDNA probes (for details see refs 17, 20, 25, 27, 28, 31, 32).

be the structural basis for differences in function among various L-type calcium channels. This hypothesis is strongly supported by the isolation of partial cDNA clones encoding various CaCB receptor-like proteins in rat aorta^[34] and brain^[35], suggesting that at least a portion of calcium channel diversity is the result of the expression of distinct CaCB receptors.

In vivo, L-type calcium channels from cardiac and smooth muscle have similar electrophysiological properties^[1,2]. The primary sequences of the cardiac and lung CaCB receptor contain identical sites that might be phosphorylated by cAMP-dependent protein kinase *in vivo*^[31,32]. However, the biochemical modulation of both channels appears to be different. cAMP-dependent phosphorylation increases the cardiac calcium current^[5,36], whereas it has little or no effect on the smooth muscle current^[37]. Therefore, stimulation of the calcium current might be not due to phosphorylation of the CaCB receptor itself. Further work involving the stable expression of the CaCB-receptor in cells exhibiting appropriate signal transduction pathways will be required to test this hypothesis.

We thank R. Nagel for expert technical assistance and H. Siepmann for the graphical work. This work was supported by Deutsche Forschungsgemeinschaft, Thyssen, and Fond der Chemischen Industrie.

References

- [1] Tsien RW, Hess P, McCleskey EW, Rosenberg RL. *Ann Rev Biophys Biophys Chem* 1987; 16: 265-90.
- [2] Bean BP. *Ann Rev Physiol* 1989; 51: 367-84.
- [3] Brown AM, Birnbaumer L. *Ann Rev Physiol* 1990; 52: 197-213.
- [4] Hofmann F, Flockerzi V, Nastainczyk W, Ruth P, Schneider T. *Current Topics Cell Reg* 1990; 31: 223-39.
- [5] Trautwein W, Hescheler J. *Ann Rev Physiol* 1990; 52: 257-73.
- [6] Yatani A, Codina J, Imoto Y, Reeves JJ.P, Birnbaumer L, Brown AM. *Science* 1987; 238: 1288-92.
- [7] Fosset M, Jaimovich E, Delpont E, Lazdunski M. *J Biol Chem* 1983; 258: 6086-92.
- [8] Catterall WA, Seagar MJ, Takahashi M. *J Biol Chem* 1988; 263: 3535-8.
- [9] Flockerzi V, Oeken J, Hofmann F. *Eur J Biochem* 1986; 161: 217-24.
- [10] Kanngiesser U, Nalik P, Pongs O. *Proc Natl Acad Sci USA* 1988; 85: 2969-73.
- [11] Leung AT, Imagawa T, Block B, Franzini-Armstrong C, Campbell KP. *J Biol Chem* 1988; 263: 994-1001.
- [12] Sieber M, Nastainczyk W, Zubor V, Wernet W, Hofmann F. *Eur J Biochem* 1987; 167: 117-22.
- [13] Flockerzi V, Oeken J, Hofmann F, Pelzer D, Cavalié A, Trautwein W. *Nature* 1986; 323: 66-8.
- [14] Vilven J, Leung AT, Imagawa T, Sharp AH, Campbell KP, Coronado R. *Biophys J* 1988; 53: 556a.
- [15] Morton ME, Caffrey JM, Brown AM, Froehner SC. *J Biol Chem* 1988; 263: 613-6.
- [16] Glossmann H, Striessnig J. *Vitamins and Hormones* 1988; 44: 154-327.
- [17] Tanabe T, Takeshima H, Mikami A, Flockerzi V *et al.* *Nature* 1987; 328: 313-8.
- [18] Röhrkasten A, Meyer HE, Nastainczyk W, Sieber M, Hofmann F. *J Biol Chem* 1988; 263: 15325-9.
- [19] Nastainczyk W, Röhrkasten A, Sieber M. *et al.* *Eur J Biochem* 1986; 169: 137-42.
- [20] Ellis SB, Williams ME, Ways NR *et al.* *Science* 1988; 241: 1661-4.
- [21] Perez-Reyes E, Kim SH, Lacerda AE *et al.* *Nature* 1989; 340: 233-6.
- [22] Kim HS, Wei X, Ruth P *et al.* *J Biol Chem* 1990; in press.
- [23] Stühmer W, Conti F, Suzuki H *et al.* *Nature* 1989; 339: 597-603.
- [24] Tanabe T, Beam KG, Powell JA, Numa S. *Nature* 1988; 336: 134-9.
- [25] Ruth P, Röhrkasten A, Biel M, Bosse E, Regulla S *et al.* *Science* 1989; 245: 1115-8.
- [26] De Jongh KS, Merrick DK, Catterall WA. *Proc Natl Acad Sci USA* 1989; 86: 8585-9.
- [27] Bosse E, Regulla S, Biel M *et al.* *FEBS Lett* 1990; 267: 153-6.
- [28] Jay SD, Ellis AB, McCue AF, Williams ME *et al.* *Science* 1990; 248: 490-2.
- [29] Endicott JA, Juranka PF, Sarangi F, Gerlach JH, Denchars KL, Ling V. *Mol Cell Biol* 1987; 7: 4075-81.
- [30] Cornwell MM, Pastan I, Gottesman MM. *J Biol Chem* 1987; 262: 2166-70.
- [31] Mikami M, Imoto K, Tanabe T *et al.* *Nature* 1989; 340: 230-3.
- [32] Biel M, Ruth P, Bosse E *et al.* *FEBS Lett* 1990; 269: 409-12.
- [33] Tanabe T, Mikami A, Numa S, Beam KG. *Nature* 1990; 344: 451-3.
- [34] Koch WJ, Hui A, Shull GE, Ellinor P, Schwartz A. *FEBS Lett.* 1989; 250: 386-8.
- [35] Snutch TP, Leonard JP, Gilbert MM, Lester HA, Davidson N. *Proc Natl Acad Sci USA* 1990; 87: 3391-5.
- [36] Kameyama M, Hofmann F, Trautwein W. *Pflügers Arch* 1985; 405: 285-93.
- [37] Welling C, Felbel J, Peper K, Hofmann F. *Naunyn-Schmiedeberg's Arch Pharmacol* 1990; 341: R62.